News
News Center
2018-12-18
Jiuzhitang Maker has established a large-scale stem cell R&D and manufacturing facility in China Pharma Valley, compliant with China’s NMPA, the EU’s EMA, and the U.S. FDA GMP standards. The facility boasts an office and production area of approximately 4,800㎡, featuring four independent B+A clean zones on its production platform—enabling the company to produce clinical-grade stem cells that meet both Chinese and U.S. pharmaceutical regulatory requirements for drug submissions.
+
2018-12-18
1. Clinical-Grade Human Bone Marrow Mesenchymal Stem Cell Injection Jiuzhitang Maker offers three specifications of the Stempanacel® product, containing 1 million, 15 million, and 50 million cells, respectively. Customized cell counts tailored to specific user needs are also available upon request. Stempanacel® products are manufactured under GMP-compliant conditions and meet quality standards that align with both U.S. FDA and China’s NMPA requirements for clinical trials. They can be directly used in preclinical animal studies or clinical trials, or, under appropriate conditions, further cultured and expanded for applications in cell biology research or other scientific investigations.
+
2018-12-18
Jiuzhitang Maker continues to ramp up its investment in research and development, actively pursuing technological innovation. As a result, the company has achieved notable progress in areas such as driving technological upgrades, safeguarding its independent intellectual property rights, and strengthening its competitive edge in technology. To date, Jiuzhitang Maker has been granted 8 patents and holds 17 copyrights for computer software.
+
2018-11-23
Notice from the State Council on Several Measures to Support Deepening Reform and Innovation in Pilot Free Trade Zones
+
2018-11-21
Notice from the Beijing Municipal Health Commission on the Announcement of the First Batch of Key Newly Added Medical Service Price Items in the Municipality for 2018
+
2018-11-14
Li Keqiang squeezes in a visit to Singapore's latest cancer therapy amid busy diplomatic engagements.
+
2018-11-09
Jiuzhitang Maker has signed a "Joint Construction Agreement for a Clinical Stem Cell Research Base" with Beijing Tiantan Hospital, Affiliated to Capital Medical University.
+
2018-11-05
On November 5, 2018, the Daxing District Development and Reform Commission and the Biomedical Base Committee delivered "Comprehensive Service Packages" to ten key high-tech enterprises in the park, offering them concierge-style support. Among these companies was Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd.
+
Here is the title—h1 placeholder text
Copyright © Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd.
Powered by: 300.cn SEO | Privacy Policy